PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

Tags

PharmaMar-Announces

More Like This

PR Newswire associated0

PharmaMar presents at ASCO that the Zepzelca®(lurbinectedin) and atezolizumab (Tecentriq®) combination significantly improves survival as first-line maintenance therapy for extensive-stage small cell lung cancer

PR Newswire associated0

PharmaMar presents encouraging results at ASCO for Small Cell Lung Cancer

ASTRAZENECA RECEIVES TWO POSITIVE NICE RECOMMENDATIONS FOR LUNG CANCER PATIENTS ACROSS ENGLAND AND WALES

Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium

PR Newswire associated0

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer